ziprasidone has been researched along with haloperidol in 149 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (3.36) | 18.2507 |
| 2000's | 77 (51.68) | 29.6817 |
| 2010's | 61 (40.94) | 24.3611 |
| 2020's | 6 (4.03) | 2.80 |
| Authors | Studies |
|---|---|
| Ewing, FE; Furman, JS; Howard, HR; Jackson, E; Johnson, C; Lowe, JA; Maloney, PR; Morrone, J; Newman, ME; Robinson, GL; Schmidt, AW; Seeger, TF; Seymour, PA; Zorn, SH | 1 |
| De Loore, K; Gommeren, W; Janssen, PF; Lesage, AS; Leysen, JE; Luyten, WH; Schotte, A; Van Gompel, P | 1 |
| Audinot, V; Chaput, C; Conte, C; Gavaudan, S; Millan, MJ; Newman-Tancredi, A; Touzard, M; Verrièle, L | 1 |
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Ernsberger, P; Hufeisen, SJ; Jayathilake, K; Kroeze, WK; Meltzer, HY; Popadak, BA; Renock, SM; Roth, BL; Steinberg, S | 1 |
| Wermuth, CG | 1 |
| Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Huang, AS; Kim, SF; Snowman, AM; Snyder, SH; Teuscher, C | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Coolen, HK; Glennon, JC; Kruse, CG; Lange, JH; Reinders, JH; Tolboom, JT | 1 |
| Shahid, M; Walker, GB; Wong, EH; Zorn, SH | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Ablordeppey, SY; Altundas, R; Bricker, B; Jackson, T; Khan, A; Kumar, EV; Roth, BL; Zhu, XY | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Giordanetto, F; Leach, AG; Zachariae, U | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Sen, S; Sinha, N | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chappie, TA; Helal, CJ; Hou, X | 1 |
| Nakagawa, T; Nishimuta, H; Nomura, N; Yabuki, M | 1 |
| Peters, JU | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Freeman, BB; Rankovic, Z; Yang, L | 1 |
| Goff, DC; Herz, L; Kletti, N; Ko, GN; Lapierre, K; Law, CG; Posever, T; Simmons, J; Wilner, KD | 1 |
| de Boer, P; de Vries, JB; Kruse, CG; Long, SK; Westerink, BH | 1 |
| Lu, Y; Rollema, H; Schmidt, AW; Sprouse, JS; Zorn, SH | 1 |
| Kapur, S; Remington, G | 1 |
| Hilger, E; Kasper, S | 1 |
| Brook, S; Gunn, KP; Lucey, JV | 1 |
| Dekeyne, A; Gobert, A; Millan, MJ; Rivet, JM | 1 |
| Howard, HR; Lebel, LA; Schmidt, AW; Zorn, SH | 1 |
| Millan, MJ; Newman-Tancredi, A; Touzard, M; Verrièle, L | 1 |
| Dai, J; Fowler, WL; Ichikawa, J; Meltzer, HY; O'Laughlin, IA | 1 |
| Nomikos, GG; Rodriguez, DE; Shirazi-Southall, S | 1 |
| Taylor, DM | 1 |
| Bäuml, J; Hirsch, SR; Kissling, W; O'Connor, R; Power, A | 1 |
| Daniel, DG | 1 |
| Kalkman, HO; Loetscher, E | 1 |
| Abdul-Monim, Z; Neill, JC; Reynolds, GP | 1 |
| Leander, JD; Wolff, MC | 1 |
| Woods, SW | 1 |
| Tamminga, CA | 1 |
| Coffey, B | 1 |
| Correll, CU; Kane, JM; Leucht, S | 1 |
| Daniel, DG; Harrigan, EP; Swift, RH; Zimbroff, DL | 1 |
| Gaszner, G; Kosza, P | 1 |
| Lujan, E; Young, CC | 1 |
| Bryois, Ch; Sahli, Ch | 1 |
| Bobes, J; Cañas, F; Mackell, J; Rejas, J | 1 |
| Aguilar, Y; Alvarez, E; Carrió, I; Catafau, AM; Corripio, I; Mena, E; Perez, V; Puigdemont, D | 1 |
| Benattia, I; Brook, S; Romano, SJ; Siu, CO; Walden, J | 1 |
| Vieta, E | 1 |
| Cosi, C; Newman-Tancredi, A; Rollet, K; Tesori, V; Waget, A | 1 |
| Matsui-Sakata, A; Ohtani, H; Sawada, Y | 1 |
| Christensen, JD; Garver, DL; Holcomb, JA | 1 |
| Bruins Slot, LA; Kleven, MS; Newman-Tancredi, A | 1 |
| Brown, FW; Greco, KE; Tune, LE; Van Horn, WA | 1 |
| Baser, O; Engelhart, L; Finkel, S; Greenspan, A; Kozma, C; Long, S; Mahmoud, R | 1 |
| Artigas, F; Bortolozzi, A; Celada, P; Díaz-Mataix, L; Scorza, MC; Toth, M | 1 |
| Giller, E; Kane, JM; Khanna, S; Rajadhyaksha, S | 1 |
| Francis, A; Kohen, I; Preval, H; Southard, R | 1 |
| Birinyi-Strachan, L; Davey, P; Kongsakon, R; Leelahanaj, T; Price, N | 1 |
| Brook, S; Citrome, L; Czobor, P; Loebel, A; Mandel, FS; Volavka, J | 1 |
| Keck, PE; Strawn, JR | 1 |
| Gearhart, DA; Hohnadel, E; Mahadik, SP; Nasrallah, HA; Parikh, V; Pillai, A; Terry, AV; Warner, S | 1 |
| Doraiswamy, PM; Levine, JG; Szarfman, A; Tonning, JM | 1 |
| de Beaurepaire, R; Even, PC; Lacroix, M; Minet-Ringuet, J; Tomé, D | 1 |
| Carpéné, C; Daviaud, D; de Beaurepaire, R; Even, PC; Minet-Ringuet, J; Prévot, D; Quignard-Boulange, A; Tomé, D; Valet, P; Visentin, V | 1 |
| Cañas, F; Díaz, S; Pérez-Solá, V; Rejas, J | 1 |
| Bartlett, MG; Terry, AV; Zhang, G | 1 |
| Neill, JC; Snigdha, S | 1 |
| Calabrese, JR; Gajwani, P; Ganocy, SJ; Gao, K; Kemp, DE; Muzina, DJ | 1 |
| Boter, H; Davidson, M; Dollfus, S; Fleischhacker, WW; Gaebel, W; Galderisi, S; Gheorghe, MD; Grobbee, DE; Hranov, LG; Hummer, M; Kahn, RS; Keet, IP; Libiger, J; Lindefors, N; López-Ibor, JJ; Peuskens, J; Riecher-Rössler, A; Rybakowski, JK; Vergouwe, Y | 1 |
| Allingham, B; Citrome, L; Jaffe, A; Levine, J; Martello, D | 1 |
| Romeo, F; Rossi, A; Tiradritti, P; Vita, A | 1 |
| Aliaga, M; Assié, MB; Barbara, M; Bardin, L; Carilla-Durand, E; Malfètes, N; Maraval, M; Newman-Tancredi, A | 1 |
| Choi, SM; Kim, NR; Kim, YH; Lee, CH; Lee, JG; Lee, SJ; Park, SW | 2 |
| Alvarez, Jdo N; Carvalho, Rde C; Frussa-Filho, R; Fukushiro, DF; Ribeiro, LT; Ricardo, VP | 1 |
| English, PA; Keller, D; Loebel, AD; Miceli, J; Ramey, T; Vieta, E | 1 |
| Harvey, PD; Kremer, CM; Lombardo, I; Pappadopulos, E | 1 |
| Ayesa, R; Crespo-Facorro, B; Martínez-Garcia, O; Mata, I; Pérez-Iglesias, R; Ramirez-Bonilla, M; Rodríguez-Sánchez, JM; Vázquez-Barquero, JL | 1 |
| Loebel, AD; Potkin, SG; Siu, CO; Warrington, LE; Watsky, EJ; Weiden, PJ | 1 |
| Auclair, AL; Barret-Grévoz, C; Barreto, M; Depoortère, R; Kleven, MS; Newman-Tancredi, A | 1 |
| Goldberg, TE; Gomar, JJ | 1 |
| Akkaya, C; Alptekin, K; Brook, S; Danaci, AE; El Tallawy, H; Hafez, J; Karayal, ON; Lowe, W; Tzebelikos, E; Ucok, A | 1 |
| Endicott, JM; Harvey, PD; Loebel, AD | 1 |
| Herman, BK; Lawson, WB; Lazariciu, I; Loebel, A; Malik, M | 1 |
| Balas, MC | 1 |
| Bernard, GR; Canonico, AE; Carson, SS; Dittus, RS; Ely, EW; Girard, TD; Meltzer, HY; Pandharipande, PP; Pun, BT; Schmidt, GA; Shintani, AK; Thompson, JL; Wright, PE | 1 |
| Anziano, R; Harrigan, RH; Miceli, JJ; O'Gorman, C; Shiovitz, T; Tensfeldt, TG | 1 |
| Ambesi-Impiombato, A; de Bartolomeis, A; Fiore, G; Iasevoli, F; Muscettola, G; Panariello, F | 1 |
| Burns, T; Derks, EM; Fleischhacker, WW; Gaebel, W; Kahn, RS; Riesbeck, M; Rössler, W; von Wilmsdorff, M | 1 |
| Holdridge, KC; Houston, JP; Saunders, W; Sorsaburu, S | 1 |
| Benedetti, AM; Frazee, LA; Leung, JG; Myers, N | 1 |
| Anziano, RJ; Harrigan, RH; Miceli, JJ; O'Gorman, C; Shiovitz, T; Tensfeldt, TG | 1 |
| Albaugh, VL; Breazeale, S; Elich, TD; Ilkayeva, O; Joyal, JL; Lang, CH; Lynch, CJ; Maresca, KP; Vary, TC; Wenner, BR | 1 |
| Bramness, JG; Gjerden, P; Slørdal, L | 1 |
| Harvey, PD; Loebel, A; Malla, A; Newcomer, JW; Potkin, SG; Romano, S; Siu, CO; Stahl, SM; Watsky, E; Weiden, PJ | 1 |
| Bouvier, ML; Gaebel, W; Henning, U; Schmitt, A; von Wilmsdorff, M | 1 |
| Kim, LW; Kim, YH; Lee, BJ; Lee, CH; Lee, JG; Park, SW; Shin, BS | 1 |
| Lombardo, I; Mandel, FS; Pappadopulos, E; Vieta, E | 1 |
| Baldaçara, L; Cordeiro, DC; Jackoswski, AP; Sanches, M | 1 |
| Bitter, I; Czobor, P; Derks, EM; Fleischhacker, WW; Kahn, RS; Libiger, J; Volavka, J | 1 |
| Andreotti, S; Gattaz, WF; Lima, FB; Passos-Bueno, MR; Sertié, AL; Sertié, RA; Suzuki, AM | 1 |
| Citrome, L; Hochfeld, M; Meng, X; Stahl, SM | 1 |
| Dudova, I; Hrdlicka, M; Urbanek, T; Zedkova, I | 1 |
| Benninghoff, J; Dehning, S; Genius, J; Grunze, H; Möller, HJ; Rujescu, D; Schindler, C; Schloesser, RJ; van der Ven, A; Wiltfang, J | 1 |
| Bitter, I; Bucci, P; Fleischhacker, WW; Galderisi, S; Kahn, RS; Libiger, J; Mucci, A | 1 |
| Capapey, J; Colom, F; Goikolea, JM; Grande, I; Sanchez-Moreno, J; Torres, I; Undurraga, J; Valentí, M; Vieta, E | 1 |
| Adams, CE; Jones, H; Powney, MJ | 1 |
| Deng, H; Gao, C; Karayal, ON; Li, K; Pan, S; Shi, J; Shu, L; Tang, H; Vanderburg, D; Wang, G; Wang, X; Xie, S; Xu, X; Zhang, H; Zhao, J | 1 |
| Dietrich-Muszalska, A; Kopka, J; Kwiatkowska, A | 1 |
| Frisch, J; Hiemke, C; Holthoewer, D; Kirschbaum, KM; Schmitt, U | 1 |
| Citrome, L; Czobor, P; Van Dorn, RA; Volavka, J | 1 |
| Baldaia, MA; Berro, LF; Frussa-Filho, R; Hollais, AW; Longo, BM; Marinho, EA; Oliveira-Lima, AJ; Santos, R; Wuo-Silva, R | 1 |
| Berro, LF; Carvalho, RC; Frussa-Filho, R; Fukushiro, DF; Hollais, AW; Kameda, SR; Patti, CL; Zanin, KA | 1 |
| Bahramzi, M; Campillo, A; Minassian, A; Vilke, GM; Wilson, MP | 1 |
| Aguglia, E; Bianchini, O; Cannavò, D; De Ronchi, D; Nespeca, C; Porcelli, S; Serretti, A; Trappoli, A | 1 |
| Fujita, M; Hagino, Y; Hashimoto, M; Ikeda, K; Kasai, S; Kobayashi, K; Meltzer, HY; Setogawa, S; Yamaura, H; Yanagihara, D | 1 |
| Brown, JB; Kadoyama, K; Kimura, G; Miki, I; Nakamura, T; Nisiguchi, K; Okuno, Y; Sakaeda, T | 1 |
| Fleischhacker, WW; Karayal, ON; Kemmler, G; Kolluri, S; Vanderburg, D; Widschwendter, CG | 1 |
| Barbosa, DS; Bonifácio, KL; Brinholi, FF; Casagrande, R; Farias, CC; Higachi, L; Moreira, EG | 1 |
| Crespo-Facorro, B; Gomez-Arnau, J; Juncal-Ruiz, M; Martinez-Garcia, O; Neergaard, KD; Ortiz-Garcia de la Foz, V; Ramirez-Bonilla, M; Suarez-Pinilla, P; Tabares-Seisdedos, R | 1 |
| Cao, D; Kang, B; Meng, Y; Ning, H; Wang, H; Xie, S | 1 |
| Cole, JB; Collins, JD; Driver, BE; Fagerstrom, E; Hessel, M; Horton, GB; Klein, LR; Martel, ML; Miner, JR; Satpathy, R | 1 |
| Dickert, NW; Sugarman, J | 2 |
| Bottlender, R; Jäger, M; Laux, G; Möller, HJ; Musil, R; Obermeier, M; Riedel, M; Schennach, R; Schmauss, M; Spellmann, I | 1 |
| Bleck, TP | 1 |
| Bernard, GR; Boehm, LM; Bowton, DL; Brummel, NE; Carson, SS; Chandrasekhar, R; Dittus, RS; Douglas, IS; Ely, EW; Exline, MC; Feinstein, DJ; Girard, TD; Gong, MN; Hite, RD; Hough, CL; Hughes, CG; Hyzy, RC; Jackson, JC; Khan, B; Malhotra, A; Masica, AL; Owens, RL; Pandharipande, PP; Patel, MB; Pisani, MA; Pun, BT; Rock, P; Schmidt, GA; Schweickert, WD; Stollings, JL; Strength, C; Thompson, JL | 1 |
| Nordstrom, K; Wilson, M; Zeller, S | 1 |
| Cole, JB; Driver, BE; Klein, LR; Martel, ML; Miner, JR | 2 |
| Tenser, RB | 1 |
| Lee, HB; Neufeld, KJ; Oldham, MA | 1 |
| Ishiki, H; Satomi, E; Shimizu, K | 1 |
| Ely, EW; Girard, TD | 1 |
| April, MD; De Lorenzo, RA; Schauer, SG; Wheeler, AR | 1 |
| Bernhard, M; Beynon, C; Brenner, T; Dietrich, M; Hecker, A; Jungk, C; Michalski, D; Nusshag, C; Reuß, CJ; Schmidt, K; Weigand, MA | 1 |
| Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S | 1 |
| Ayesa-Arriola, R; Crespo-Facorro, B; Gómez-Revuelta, M; Juncal-Ruiz, M; Pelayo-Terán, JM; Romero-Jiménez, R; Setién Suero, E; Suárez-Pinilla, P; Vázquez-Bourgon, J | 1 |
| Coralic, Z; Rader, ES; Vinson, DR; Wilson, MP | 1 |
| Cao, D; Hong, Y; Huang, W; Wang, L; Wei, H; Xu, J; Zhang, J | 1 |
| Chen, Q; Deng, W; Du, X; Hao, Q; Hu, X; Li, C; Li, K; Li, L; Li, T; Li, X; Lu, T; Lv, L; Ma, X; Ren, H; Tan, L; Tan, Q; Tang, Y; Wang, C; Wang, L; Wang, Q; Wang, Y; Wu, Y; Yan, H; Yang, F; Yang, G; Yang, J; Yu, H; Yue, W; Zhang, D; Zhang, F; Zhang, G; Zhang, H; Zhang, Y; Zhao, L | 1 |
18 review(s) available for ziprasidone and haloperidol
| Article | Year |
|---|---|
Selective optimization of side activities: another way for drug discovery.
Topics: Animals; Biological Availability; Combinatorial Chemistry Techniques; Databases, Factual; Drug Design; Humans; Patents as Topic; Pharmaceutical Preparations; Structure-Activity Relationship | 2004 |
Polypharmacology - foe or friend?
Topics: Animals; Communicable Diseases; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Polypharmacology; Safety | 2013 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Practical approaches to evaluating and optimizing brain exposure in early drug discovery.
Topics: Animals; Blood-Brain Barrier; Central Nervous System; Central Nervous System Agents; Drug Delivery Systems; Drug Discovery; Humans; Molecular Structure; Structure-Activity Relationship | 2019 |
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; Dopamine Antagonists; Drug Monitoring; Haloperidol; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Receptors, Dopamine D2; Receptors, Dopamine D4; Risperidone; Schizophrenia; Schizophrenic Psychology; Serotonin Antagonists; Sulpiride; Thiazoles; Treatment Outcome | 2001 |
[Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders].
Topics: Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Dibenzothiepins; Haloperidol; Humans; Imidazoles; Indoles; Multicenter Studies as Topic; Olanzapine; Piperazines; Pirenzepine; Placebos; Quetiapine Fumarate; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sulpiride; Thiazoles | 2000 |
Recent developments in pharmacotherapy for the acutely psychotic patient.
Topics: Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Injections, Intramuscular; Olanzapine; Piperazines; Pirenzepine; Psychomotor Agitation; Psychotic Disorders; Thiazoles | 2002 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Therapeutic Equivalency; Thiazoles | 2003 |
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Child; Dibenzothiazepines; Double-Blind Method; Dyskinesia, Drug-Induced; Haloperidol; Humans; Middle Aged; Neurologic Examination; Olanzapine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risk; Sulpiride; Thiazoles | 2004 |
[Paralytic ileus during haloperidol therapy].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Fatal Outcome; Haloperidol; Humans; Intestinal Pseudo-Obstruction; Male; Piperazines; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2004 |
[Psychotropics and weight gain].
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Child; Clozapine; Dibenzothiazepines; Double-Blind Method; Female; Fructose; Haloperidol; Humans; Imidazoles; Indoles; Male; Obesity; Olanzapine; Piperazines; Placebos; Psychotropic Drugs; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Socioeconomic Factors; Sulpiride; Thiazoles; Time Factors; Topiramate; Valproic Acid; Weight Gain | 2004 |
The treatment of mixed states and the risk of switching to depression.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Electroconvulsive Therapy; Haloperidol; Health Education; Humans; Lithium Carbonate; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Thiazoles | 2005 |
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Double-Blind Method; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Research Design; Risperidone; Schizophrenia; Sleep Stages; Thiazoles; Treatment Outcome | 2008 |
Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Depression; Depressive Disorder; Dibenzothiazepines; Double-Blind Method; Drug Industry; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Research Support as Topic; Risperidone; Thiazoles | 2013 |
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).
Topics: Aggression; Antipsychotic Agents; Aripiprazole; Clopenthixol; Dystonia; Haloperidol; Humans; Lorazepam; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Sleep; Thiazoles | 2012 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes | 2020 |
Haloperidol Versus Ziprasidone With Concomitant Medications and Other Predictors of Physical Restraint Duration in the Emergency Department.
Topics: Antipsychotic Agents; Emergency Service, Hospital; Haloperidol; Humans; Piperazines; Psychomotor Agitation; Restraint, Physical; Retrospective Studies; Thiazoles | 2022 |
A cumulative Bayesian network meta-analysis on the comparative efficacy of pharmacotherapies for mania over the last 40 years.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Carbamazepine; Dibenzocycloheptenes; Haloperidol; Humans; Lithium; Mania; Network Meta-Analysis; Olanzapine; Paliperidone Palmitate; Pharmaceutical Preparations; Piperazines; Quetiapine Fumarate; Risperidone; Tamoxifen; Thiazoles; Valproic Acid | 2022 |
36 trial(s) available for ziprasidone and haloperidol
| Article | Year |
|---|---|
An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Hospitalization; Humans; Male; Middle Aged; Neurologic Examination; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 1998 |
Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group.
Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Drug Administration Schedule; Female; Haloperidol; Hospitalization; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychotic Disorders; Severity of Illness Index; Thiazoles; Treatment Outcome | 2000 |
A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Nausea; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Sleep Initiation and Maintenance Disorders; Thiazoles; Treatment Outcome; Vomiting | 2002 |
The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Interactions; Endpoint Determination; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Thiazoles; Time Factors | 2004 |
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Dyskinesia, Drug-Induced; Follow-Up Studies; Haloperidol; Hospitalization; Humans; Mental Disorders; Models, Econometric; Olanzapine; Outpatients; Patient Compliance; Piperazines; Psychiatric Status Rating Scales; Retrospective Studies; Risperidone; Sensitivity and Specificity; Spain; Survival Analysis; Thiazoles; Treatment Outcome; Weight Gain | 2004 |
Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzamides; Drug Resistance; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Neostriatum; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Pyrrolidines; Radiopharmaceuticals; Receptors, Dopamine D2; Single-Blind Method; Thiazoles; Tomography, Emission-Computed, Single-Photon; Treatment Failure | 2005 |
Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study.
Topics: Acute Disease; Administration, Oral; Adult; Affective Disorders, Psychotic; Brief Psychiatric Rating Scale; Demography; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Manifest Anxiety Scale; Piperazines; Schizophrenia; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome; Withholding Treatment | 2005 |
Cerebral cortical gray expansion associated with two second-generation antipsychotics.
Topics: Adult; Antipsychotic Agents; Atrophy; Cerebral Cortex; Cognition Disorders; Female; Follow-Up Studies; Haloperidol; Humans; Magnetic Resonance Imaging; Male; Nerve Growth Factors; Piperazines; Psychiatric Status Rating Scales; Quality of Life; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2005 |
Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chlorpromazine; Double-Blind Method; Drug Resistance; Female; Haloperidol; Humans; Male; Piperazines; Prolactin; Schizophrenia; Thiazoles; Time Factors | 2006 |
Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Female; Haloperidol; Hospitalization; Hostility; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2006 |
Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Cost of Illness; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Haloperidol; Hospital Costs; Humans; Injections, Intramuscular; Length of Stay; Male; Piperazines; Quality of Life; Research Design; Schizophrenia; Spain; Thiazoles; Treatment Outcome | 2007 |
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol; Humans; Linear Models; Male; Olanzapine; Patient Compliance; Piperazines; Proportional Hazards Models; Quetiapine Fumarate; Schizophrenia; Sulpiride; Thiazoles; Treatment Outcome | 2008 |
Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Female; Haloperidol; Humans; India; Male; Middle Aged; Patient Dropouts; Piperazines; Placebo Effect; Psychiatric Status Rating Scales; Russia; Thiazoles; Time Factors; Treatment Outcome; United States; Young Adult | 2010 |
Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidol.
Topics: Adult; Antipsychotic Agents; Chi-Square Distribution; Cognition Disorders; Double-Blind Method; Female; Haloperidol; Humans; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome | 2009 |
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cognition Disorders; Female; Follow-Up Studies; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Perphenazine; Piperazines; Prospective Studies; Psychotic Disorders; Risperidone; Severity of Illness Index; Sulpiride; Thiazoles | 2009 |
Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Patient Dropouts; Piperazines; Psychiatric Status Rating Scales; Quality of Life; Remission Induction; Schizophrenia; Schizophrenic Psychology; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2009 |
Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles | 2009 |
The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Middle Aged; Patient Admission; Piperazines; Psychiatric Status Rating Scales; Psychometrics; Thiazoles | 2008 |
Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Black People; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2009 |
Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial.
Topics: Adult; Aged; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; Humans; Intensive Care Units; Length of Stay; Male; Middle Aged; Piperazines; Postoperative Complications; Psychiatric Status Rating Scales; Respiration, Artificial; Thiazoles; Treatment Outcome | 2010 |
Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Electrocardiography; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles | 2010 |
Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Medication Adherence; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quetiapine Fumarate; ROC Curve; Schizophrenia; Schizophrenic Psychology; Sulpiride; Surveys and Questionnaires; Thiazoles; Treatment Outcome | 2010 |
Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Aged; Antipsychotic Agents; Blood Pressure; Dose-Response Relationship, Drug; Electrocardiography; Female; Haloperidol; Heart Rate; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Schizophrenia; Single-Blind Method; Thiazoles; Young Adult | 2010 |
A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Haloperidol; Humans; Piperazines; Psychiatric Status Rating Scales; Quality of Life; Remission Induction; Schizophrenia; Schizophrenic Psychology; Thiazoles; Time Factors; Treatment Outcome | 2010 |
Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Emergency Services, Psychiatric; Female; Haloperidol; Humans; Hypnotics and Sedatives; Injections, Intramuscular; Male; Midazolam; Olanzapine; Piperazines; Promethazine; Psychomotor Agitation; Psychotic Disorders; Thiazoles; Tranquilizing Agents | 2011 |
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Haloperidol; Hostility; Humans; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Schizophrenic Psychology; Sulpiride; Thiazoles; Treatment Outcome | 2011 |
Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Labeling; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2012 |
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Piperazines; Psychomotor Disorders; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Schizophrenic Psychology; Sulpiride; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; China; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Injections, Intramuscular; Least-Squares Analysis; Male; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Schizophrenia; Thiazoles; Time Factors; Young Adult | 2013 |
Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Hostility; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Thiazoles | 2014 |
Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Double-Blind Method; Haloperidol; Humans; Middle Aged; Piperazines; Schizophrenia; Severity of Illness Index; Thiazoles; Young Adult | 2015 |
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Haloperidol; Humans; Incidence; Male; Olanzapine; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Young Adult | 2017 |
Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Interpersonal Relations; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Risk Assessment; Schizophrenia; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome | 2019 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; Female; Haloperidol; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Respiratory Insufficiency; Shock; Thiazoles; Treatment Failure | 2018 |
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Haloperidol; Humans; Male; Olanzapine; Outcome Assessment, Health Care; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Young Adult | 2020 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fumarate; Risperidone; Schizophrenia; Treatment Outcome | 2023 |
95 other study(ies) available for ziprasidone and haloperidol
| Article | Year |
|---|---|
3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Brain; Catalepsy; Clozapine; Dopamine; Drug Design; Humans; Molecular Structure; Phosphatidylinositols; Piperazines; Prazosin; Rats; Receptors, Adrenergic; Receptors, Dopamine; Serotonin Antagonists; Thiazoles | 1996 |
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
Topics: Animals; Antipsychotic Agents; Brain; Cells, Cultured; Clozapine; Haloperidol; Humans; Male; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Serotonin; Risperidone | 1996 |
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
Topics: Animals; Antipsychotic Agents; CHO Cells; Cricetinae; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin Agents; Sulfur Radioisotopes | 1998 |
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Humans; Protein Binding; Receptors, Histamine H1; Statistics, Nonparametric; Weight Gain | 2003 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
Topics: Adenylate Kinase; Animals; Antipsychotic Agents; Enzyme Activation; Hypothalamus; Immunohistochemistry; Mice; Phosphorylation; Receptors, Histamine H1; Weight Gain | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolactinemia; Indoles; Metabolic Diseases; Phthalimides; Piperazines; Principal Component Analysis; Pyridines; Radioligand Assay; Receptors, Biogenic Amine; Weight Gain | 2007 |
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.
Topics: Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Cloning, Molecular; Clozapine; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Histamine Release; Humans; Inhibitory Concentration 50; Molecular Structure; Olanzapine; Psychotropic Drugs; Radioligand Assay; Receptors, Adrenergic; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Muscarinic; Receptors, Serotonin; Schizophrenia; Substrate Specificity | 2009 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
Topics: Animals; Antipsychotic Agents; Apomorphine; Azepines; Butyrophenones; Clozapine; Haloperidol; Lethal Dose 50; Male; Mice; Molecular Structure; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Structure-Activity Relationship | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Topics: Binding Sites; Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Ligands; Models, Molecular; Potassium Channel Blockers; Protein Binding; Protein Conformation | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Current landscape of phosphodiesterase 10A (PDE10A) inhibition.
Topics: Animals; Cyclic AMP; Cyclic GMP; Humans; Hydrolysis; Mice; Models, Molecular; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats | 2012 |
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
Topics: Cytosol; Haloperidol; Humans; Intestinal Mucosa; Intestines; Liver; Mebendazole; NADP; Oxidation-Reduction; Piperazines; Thiazoles | 2013 |
Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Dopamine; Dopamine Agonists; Extracellular Space; Haloperidol; Male; Norepinephrine; Olanzapine; Piperazines; Pirenzepine; Prefrontal Cortex; Rats; Rats, Wistar; Reference Values; Risperidone; Tetrahydronaphthalenes; Thiazoles | 1998 |
5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Chromatography, High Pressure Liquid; Clozapine; Corpus Striatum; Dopamine; Haloperidol; Male; Microdialysis; Olanzapine; Piperazines; Pirenzepine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Sensitivity and Specificity; Synaptic Transmission; Thiazoles; Time Factors | 2000 |
Generalization of serotonin (5-HT)1A agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminative stimuli elicited by PD128,907 and 7-OH-DPAT.
Topics: Animals; Antipsychotic Agents; Benzopyrans; Clozapine; Discrimination Learning; Dopamine; Dopamine Agonists; Haloperidol; Humans; Male; Oxazines; Piperazines; Pyrrolidines; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin; Serotonin Receptor Agonists; Tetrahydronaphthalenes; Thiazoles | 2001 |
Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Binding Sites; Binding, Competitive; Cell Line; Clozapine; Dibenzothiazepines; Dopamine Antagonists; Haloperidol; Humans; Neurons; Norepinephrine; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Rats; Receptors, Adrenergic, alpha; Receptors, Dopamine; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Risperidone; Serotonin; Serotonin Antagonists; Thiazoles | 2001 |
Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation.
Topics: Animals; Antipsychotic Agents; Binding, Competitive; Chlorpromazine; CHO Cells; Clozapine; Cricetinae; Dose-Response Relationship, Drug; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Haloperidol; Humans; Membranes; Piperazines; Piperidines; Pyridines; Pyrimidinones; Pyrrolidines; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Thiazoles; Thioridazine; Tritium | 2001 |
Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Cholinesterase Inhibitors; Clozapine; Corpus Striatum; Haloperidol; Male; Nucleus Accumbens; Olanzapine; Oxotremorine; Piperazines; Pirenzepine; Rats; Rats, Sprague-Dawley; Risperidone; Scopolamine; Sulpiride; Thiazoles; Thioridazine | 2002 |
Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Dialysis Solutions; Dopamine Antagonists; Extracellular Space; Haloperidol; Hippocampus; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Microdialysis; Olanzapine; Piperazines; Pirenzepine; Rats; Rats, Wistar; Risperidone; Serotonin Antagonists; Thiazoles; Thioridazine | 2002 |
Prolongation of QTc interval and antipsychotics.
Topics: Antipsychotic Agents; Death, Sudden, Cardiac; Drug Administration Schedule; Drug Labeling; Drug Monitoring; Haloperidol; Humans; Long QT Syndrome; Piperazines; Risperidone; Thiazoles | 2002 |
alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brimonidine Tartrate; Chlorpromazine; CHO Cells; Clozapine; Cricetinae; Cyclic AMP; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Humans; Isoxazoles; Norepinephrine; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quetiapine Fumarate; Quinolones; Quinoxalines; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D2; Risperidone; Thiazoles; Transfection; Yohimbine | 2003 |
The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cognition Disorders; Excitatory Amino Acid Antagonists; Female; Haloperidol; Injections, Intraperitoneal; Phencyclidine; Piperazines; Rats; Reversal Learning; Social Isolation; Thiazoles | 2003 |
Comparison of the effects of antipsychotics on a delayed radial maze task in the rat.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Dose-Response Relationship, Drug; Food Deprivation; Haloperidol; Male; Maze Learning; Memory; Olanzapine; Piperazines; Pirenzepine; Rats; Rats, Sprague-Dawley; Risperidone; Thiazoles | 2003 |
Similarities and differences among antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2003 |
Clinical case presentation: therapeutic challenges in adolescent-onset bipolar disorder.
Topics: Adolescent; Aggression; Anti-Anxiety Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Clonazepam; Diagnosis, Differential; Education; Family; GABA Modulators; Haloperidol; Hospitalization; Humans; Irritable Mood; Lithium; Lorazepam; Male; Piperazines; Psychiatric Status Rating Scales; Sexual Behavior; Thiazoles; Valproic Acid | 2003 |
Intravenous ziprasidone for treatment of delirium in the intensive care unit.
Topics: Antipsychotic Agents; Bone Transplantation; Critical Care; Delirium; Haloperidol; Humans; Male; Middle Aged; Piperazines; Postoperative Complications; Thiazoles | 2004 |
Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
Topics: Aminopyridines; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Agonists; Haloperidol; Kainic Acid; Male; Mice; Mice, Inbred C57BL; Piperazines; Piperidines; Pyridines; Quinolones; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Thiazoles | 2005 |
Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Risperidone; Schizophrenia; Thiazoles | 2005 |
Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Dioxanes; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Excitatory Amino Acid Antagonists; Haloperidol; Interpersonal Relations; Male; Phencyclidine; Piperazines; Pyridines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Remoxipride; Serotonin Antagonists; Serotonin Receptor Agonists; Thiazoles; Tropanes | 2005 |
A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Arrhythmias, Cardiac; Dementia; Electrocardiography; Female; Haloperidol; Humans; Injections, Intramuscular; Long QT Syndrome; Male; Middle Aged; Piperazines; Psychomotor Agitation; Retrospective Studies; Risk Factors; Thiazoles; Torsades de Pointes | 2005 |
Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cerebrovascular Disorders; Cohort Studies; Dementia; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Haloperidol; Hospitalization; Humans; Male; Middle Aged; Olanzapine; Patient Admission; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Risk Factors; Risperidone; Thiazoles | 2005 |
Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action.
Topics: Animals; Antipsychotic Agents; Benzopyrans; Dopamine; Electrophysiology; Extracellular Fluid; Haloperidol; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neural Pathways; Neurons; Osmolar Concentration; Piperazines; Prefrontal Cortex; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Thiazoles; Ventral Tegmental Area | 2005 |
Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Databases, Factual; Emergency Medical Services; Emergency Service, Hospital; Female; Haloperidol; Humans; Hypnotics and Sedatives; Injections, Intramuscular; Lorazepam; Male; Piperazines; Psychomotor Agitation; Retrospective Studies; Thiazoles; Treatment Outcome | 2005 |
Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Topics: Antipsychotic Agents; Benzodiazepines; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Dibenzothiazepines; Drug Costs; Haloperidol; Health Care Costs; Humans; Models, Econometric; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thailand; Thiazoles; Treatment Outcome | 2005 |
Early bicarbonate loading and dantroline for ziprasidone/haloperidol-induced neuroleptic malignant syndrome.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Combined Modality Therapy; Dantrolene; Disruptive, Impulse Control, and Conduct Disorders; Drug Administration Schedule; Fluid Therapy; Haloperidol; Humans; Male; Muscle Relaxants, Central; Neuroleptic Malignant Syndrome; Piperazines; Self-Injurious Behavior; Sodium Bicarbonate; Thiazoles | 2006 |
Time-dependent effects of haloperidol and ziprasidone on nerve growth factor, cholinergic neurons, and spatial learning in rats.
Topics: Animals; Antipsychotic Agents; Autoradiography; Brain Chemistry; Choline O-Acetyltransferase; Darkness; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Haloperidol; Image Processing, Computer-Assisted; Immunohistochemistry; Light; Male; Maze Learning; Motor Activity; Nerve Growth Factors; Nerve Tissue Proteins; Neurons; Parasympathetic Nervous System; Piperazines; Rats; Rats, Wistar; Receptors, Muscarinic; Receptors, Nicotinic; Thiazoles; Time Factors | 2006 |
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Amenorrhea; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Clozapine; Dibenzothiazepines; Female; Galactorrhea; Gynecomastia; Haloperidol; Humans; Hyperprolactinemia; Male; Olanzapine; Piperazines; Pituitary Neoplasms; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Sex Factors; Thiazoles; United States; United States Food and Drug Administration | 2006 |
A model for antipsychotic-induced obesity in the male rat.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Weight; Circadian Rhythm; Diet; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Feeding Behavior; Haloperidol; Male; Obesity; Olanzapine; Piperazines; Rats; Rats, Sprague-Dawley; Thiazoles; Time Factors; Weight Gain | 2006 |
Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment.
Topics: Adipocytes; Animals; Antipsychotic Agents; Benzodiazepines; Cell Size; Drug Administration Schedule; Fatty Acid Synthases; Gene Expression Regulation; Glucose Transport Proteins, Facilitative; Haloperidol; Lipid Metabolism; Male; Obesity; Olanzapine; Piperazines; Rats; Rats, Sprague-Dawley; RNA; Statistics, Nonparametric; Sterol Esterase; Thiazoles; Weight Gain | 2007 |
Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chromatography, Liquid; Clozapine; Haloperidol; Isoxazoles; Male; Olanzapine; Paliperidone Palmitate; Piperazines; Pyrimidines; Rats; Reproducibility of Results; Risperidone; Tandem Mass Spectrometry; Thiazoles | 2007 |
Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats--a preliminary investigation.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Disease Models, Animal; Drug Interactions; Excitatory Amino Acid Antagonists; Female; Haloperidol; Matched-Pair Analysis; Phencyclidine; Piperazines; Rats; Rats, Inbred Strains; Schizophrenia; Schizophrenic Psychology; Social Behavior; Social Behavior Disorders; Thiazoles | 2008 |
Did CATIE influence antipsychotic use?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy; Haloperidol; Humans; Olanzapine; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles | 2008 |
Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Patient Compliance; Piperazines; Quality of Life; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2008 |
The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Benzofurans; Benzoxazoles; Benzylamines; Blood Glucose; Clozapine; Corticosterone; Cyclopentanes; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Haloperidol; Male; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Thiazoles | 2008 |
Differential effects of ziprasidone and haloperidol on immobilization stress-induced mRNA BDNF expression in the hippocampus and neocortex of rats.
Topics: Animals; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Gene Expression; Haloperidol; Hippocampus; In Situ Hybridization; Injections, Intraperitoneal; Male; Neocortex; Piperazines; Rats; Rats, Sprague-Dawley; Restraint, Physical; RNA, Messenger; Stress, Psychological; Thiazoles | 2009 |
Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cocaine; Cocaine-Related Disorders; Haloperidol; Humans; Male; Mice; Motor Activity; Piperazines; Schizophrenia; Substance Withdrawal Syndrome; Thiazoles | 2008 |
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Benzamides; Benzodiazepines; Benzoxazoles; Catalepsy; Clozapine; Dibenzothiazepines; Dioxanes; Dopamine Antagonists; Female; Haloperidol; Macaca fascicularis; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Remoxipride; Risperidone; Serotonin Receptor Agonists; Thiazoles; Tropanes; Video Recording | 2009 |
Targeting cognition in schizophrenia research: from etiology to treatment.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Dibenzothiazepines; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Reaction Time; Schizophrenia; Sulpiride; Thiazoles | 2009 |
Free your MIND and the rest will follow: decoding delirium in the intensive care unit.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Intensive Care Units; Piperazines; Postoperative Complications; Respiration, Artificial; Thiazoles; Treatment Outcome | 2010 |
Pattern of acute induction of Homer1a gene is preserved after chronic treatment with first- and second-generation antipsychotics: effect of short-term drug discontinuation and comparison with Homer1a-interacting genes.
Topics: Animals; Antipsychotic Agents; Basal Ganglia; Carrier Proteins; Cerebral Cortex; Disks Large Homolog 4 Protein; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Homer Scaffolding Proteins; Inositol 1,4,5-Trisphosphate Receptors; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Piperazines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Thiazoles; Time Factors; Up-Regulation | 2011 |
Characteristics and mortality among hospitalized patients treated with intramuscular antipsychotics: analysis of a United States hospital database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Databases, Factual; Female; Haloperidol; Hospital Mortality; Humans; Injections, Intramuscular; Male; Olanzapine; Piperazines; Thiazoles; United States; Young Adult | 2010 |
Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Costs; Female; Haloperidol; Humans; Injections, Intramuscular; Length of Stay; Male; Middle Aged; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Retrospective Studies; Schizophrenia; Thiazoles | 2011 |
Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Carnitine; Clozapine; Energy Metabolism; Fatty Acids, Nonesterified; Female; Haloperidol; Insulin Resistance; Lipolysis; Male; Malonyl Coenzyme A; Mice; Olanzapine; Piperazines; Rats; Rats, Sprague-Dawley; Risperidone; Thiazoles; Vitamin B Complex | 2012 |
Prescription persistence and safety of antipsychotic medication: a national registry-based 3-year follow-up.
Topics: Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Chlorprothixene; Cholinergic Antagonists; Clopenthixol; Clozapine; Drug Prescriptions; Female; Follow-Up Studies; Haloperidol; Humans; Logistic Models; Male; Methotrimeprazine; Middle Aged; Mortality; Norway; Odds Ratio; Piperazines; Registries; Thiazoles | 2010 |
The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats.
Topics: Animals; Antipsychotic Agents; Blotting, Western; Clozapine; Eating; Exploratory Behavior; Haloperidol; Hypothalamus; Leptin; Male; Motor Activity; Piperazines; Rats; Rats, Wistar; Receptors, Leptin; Thiazoles; Time Factors; Weight Gain | 2010 |
Differential effects of ziprasidone and haloperidol on immobilization-stress-induced CRF mRNA expression in the hypothalamic paraventricular nucleus of rats.
Topics: Animals; Corticotropin-Releasing Hormone; Drug Evaluation, Preclinical; Haloperidol; Immobilization; Male; Paraventricular Hypothalamic Nucleus; Piperazines; Rats; Rats, Sprague-Dawley; Stress, Psychological; Thiazoles | 2011 |
Protective effects of atypical antipsychotic drugs against MPP(+)-induced oxidative stress in PC12 cells.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antipsychotic Agents; Aripiprazole; bcl-2-Associated X Protein; Benzodiazepines; Blotting, Western; Cell Survival; Haloperidol; Herbicides; Olanzapine; Oxidative Stress; PC12 Cells; Piperazines; Quinolones; Rats; Reactive Oxygen Species; Superoxide Dismutase; Thiazoles | 2011 |
Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Cultural Characteristics; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Health Status Disparities; Healthcare Disparities; Humans; India; Internationality; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Research Design; Russia; Thiazoles; Treatment Outcome; United States; Young Adult | 2011 |
Effects of antipsychotics with different weight gain liabilities on human in vitro models of adipose tissue differentiation and metabolism.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Haloperidol; Humans; Olanzapine; Piperazines; Thiazoles; Weight Gain | 2011 |
Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Medical Records; Olanzapine; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Time Factors; Treatment Outcome | 2011 |
Ziprasidone--not haloperidol--induces more de-novo neurogenesis of adult neural stem cells derived from murine hippocampus.
Topics: Animals; Antipsychotic Agents; Cell Differentiation; Cell Movement; Cells, Cultured; Epidermal Growth Factor; Fibroblast Growth Factor 2; Haloperidol; Hippocampus; Immunohistochemistry; Mice; Mice, Inbred C57BL; Neural Stem Cells; Neurogenesis; Piperazines; Receptor, Serotonin, 5-HT1A; Serotonin Antagonists; Thiazoles; Tubulin | 2013 |
The effects of ziprasidone, clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): comparison.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Haloperidol; Humans; In Vitro Techniques; Lipid Peroxidation; Male; Piperazines; Thiazoles; Thiobarbituric Acid Reactive Substances | 2013 |
Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties.
Topics: Animals; Antipsychotic Agents; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B, Member 1; Buspirone; Haloperidol; Ketanserin; Male; Mice; Mice, Knockout; Motor Activity; Piperazines; Quinolones; Rotarod Performance Test; Serotonin Antagonists; Serotonin Receptor Agonists; Thiazoles | 2013 |
Selective action of an atypical neuroleptic on the mechanisms related to the development of cocaine addiction: a pre-clinical behavioural study.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Central Nervous System Sensitization; Cocaine; Cocaine-Related Disorders; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibitors; Haloperidol; Male; Mice; Motor Activity; Piperazines; Quinolones; Thiazoles | 2014 |
Effects of acute and long-term typical or atypical neuroleptics on morphine-induced behavioural effects in mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Female; Haloperidol; Mice; Morphine; Motor Activity; Piperazines; Substance Withdrawal Syndrome; Thiazoles | 2014 |
Despite expert recommendations, second-generation antipsychotics are not often prescribed in the emergency department.
Topics: Administration, Oral; Adult; Alcoholic Intoxication; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Droperidol; Drug Prescriptions; Drug Therapy, Combination; Emergency Service, Hospital; Female; Haloperidol; Hospitals, University; Humans; Male; Middle Aged; Olanzapine; Piperazines; Practice Guidelines as Topic; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles | 2014 |
Effects of antipsychotic drugs on insight in schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Awareness; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2014 |
Involvement of cholinergic system in hyperactivity in dopamine-deficient mice.
Topics: Acetylcholine; Akathisia, Drug-Induced; Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Central Nervous System Stimulants; Choline O-Acetyltransferase; Clozapine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Extracellular Space; Haloperidol; Levodopa; Locomotion; Mice, Inbred C57BL; Piperazines; Psychomotor Agitation; Thiazoles | 2015 |
Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database.
Topics: Algorithms; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Data Mining; Databases, Factual; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Thiazoles | 2015 |
Clozapine and olanzapine are better antioxidants than haloperidol, quetiapine, risperidone and ziprasidone in in vitro models.
Topics: Antioxidants; Antipsychotic Agents; Benzodiazepines; Biphenyl Compounds; Clozapine; Free Radical Scavengers; Haloperidol; Humans; Models, Biological; Neutrophil Activation; Neutrophils; Olanzapine; Picrates; Piperazines; Quetiapine Fumarate; Reactive Oxygen Species; Risperidone; Tetradecanoylphorbol Acetate; Thiazoles | 2016 |
Effects of haloperidol, olanzapine, ziprasidone, and PHA-543613 on spatial learning and memory in the Morris water maze test in naïve and MK-801-treated mice.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Haloperidol; Male; Maze Learning; Memory; Mice; Mice, Inbred C57BL; Olanzapine; Piperazines; Quinuclidines; Schizophrenia; Spatial Learning; Thiazoles; Treatment Outcome | 2017 |
Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation in the Emergency Department.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Emergency Medical Services; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Mental Status and Dementia Tests; Midazolam; Middle Aged; Olanzapine; Piperazines; Prospective Studies; Psychomotor Agitation; Thiazoles; Treatment Outcome; Young Adult | 2018 |
Ethics and Regulatory Barriers to Research in Emergency Settings.
Topics: Emergency Service, Hospital; Haloperidol; Midazolam; Olanzapine; Piperazines; Thiazoles | 2018 |
Dopamine Antagonists in ICU Delirium.
Topics: Critical Illness; Delirium; Dopamine Antagonists; Haloperidol; Humans; Intensive Care Units; Piperazines; Thiazoles | 2018 |
Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation.
Topics: Emergency Service, Hospital; Haloperidol; Midazolam; Olanzapine; Piperazines; Thiazoles | 2019 |
In reply.
Topics: Emergency Service, Hospital; Haloperidol; Midazolam; Olanzapine; Piperazines; Thiazoles | 2019 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles | 2019 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles | 2019 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles | 2019 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness. Reply.
Topics: Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles | 2019 |
Acute Agitation and the Exception From Informed Consent Requirements.
Topics: Emergency Service, Hospital; Haloperidol; Informed Consent; Midazolam; Olanzapine; Piperazines; Thiazoles | 2019 |
In reply.
Topics: Emergency Service, Hospital; Haloperidol; Midazolam; Olanzapine; Piperazines; Thiazoles | 2019 |
In reply.
Topics: Emergency Service, Hospital; Haloperidol; Midazolam; Olanzapine; Piperazines; Thiazoles | 2019 |
[Additive therapies : Intensive care studies from 2018-2019].
Topics: Critical Care; Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles | 2020 |